Phospho-specific antibodies sales will expand through 2036, with gab2 (phospho-tyr643) antibody holding a 32.6% share in 2026 as the leading product type segment. The market was valued at USD 32.67 billion in 2025 and is expected to reach USD 97.03 billion by 2036, creating an incremental opportunity of USD 75.89 billion.